insights_auto
Pourquoi 6160 a-t-elle augmenté de 4,36%?
Approfondirchevron_right
6160:HKG
BeOne Medicines AG
225,00 HKD
arrow_upward
+4,36%(+9,40) 1J
16 oct., 16:08:14 UTC+8 · HKD
search
Tous les symboles
| Symbole | Cours | Variation | % variat. |
|---|
insights_autoGénération des principaux insights pour 6160...
Ouverture
224,80 HKD
Élevé
230,20 HKD
Faible
221,80 HKD
Cap. boursière
355,76 Md
Vol. moyen
2,93 M
Volume
4,41 M
Ratio cours/bénéfice
65,67
+ haut sur 1 an
235,60 HKD
+ bas sur 1 an
153,00 HKD
BPA
3,43 HKD
Actions en circulation
1,43 Md
Nombre d'employés
12 k
Ouverture
224,80 HKD
Élevé
230,20 HKD
Faible
221,80 HKD
Cap. boursière
355,76 Md
Vol. moyen
2,93 M
Volume
4,41 M
Ratio cours/bénéfice
65,67
+ haut sur 1 an
235,60 HKD
+ bas sur 1 an
153,00 HKD
BPA
3,43 HKD
Actions en circulation
1,43 Md
Nombre d'employés
12 k
Articles
Sources : Web et partenaires du secteur de l'information
ad-hoc-news.de
·
il y a 1 jour
Morgan Stanley lifts target for BeOne Medicines stock to USD 425.00
MarketBeat
·
il y a 2 jours
BeOne Medicines (NASDAQ:ONC) Stock: Insider Xiaodong Wang Sells 31,027 Shares
Profil
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
À propos de BeOne Medicines AG
PDGJohn Vincent Oyler | John Vincent Oyler
Employés12 k
Date de création28 oct. 2010
Siège social-
Secteur-
Site Webbeonemedicines.com